AU2001289123A1 - Compounds and methods for diagnosing and treating amyloid-related conditions - Google Patents

Compounds and methods for diagnosing and treating amyloid-related conditions

Info

Publication number
AU2001289123A1
AU2001289123A1 AU2001289123A AU8912301A AU2001289123A1 AU 2001289123 A1 AU2001289123 A1 AU 2001289123A1 AU 2001289123 A AU2001289123 A AU 2001289123A AU 8912301 A AU8912301 A AU 8912301A AU 2001289123 A1 AU2001289123 A1 AU 2001289123A1
Authority
AU
Australia
Prior art keywords
diagnosing
compounds
methods
related conditions
treating amyloid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001289123A
Inventor
Tiziano Bandiera
Allen Edwin Buhl
Donald Bainbridge Carter
Jacqueline Lansen
Cesare Pellerano
Thomas J. Raub
Luisa Savini
Steven P. Tanis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn SpA
Pharmacia and Upjohn Co
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn SpA, Pharmacia and Upjohn Co, Upjohn Co filed Critical Pharmacia and Upjohn SpA
Publication of AU2001289123A1 publication Critical patent/AU2001289123A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
AU2001289123A 2000-09-22 2001-09-17 Compounds and methods for diagnosing and treating amyloid-related conditions Abandoned AU2001289123A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23461100P 2000-09-22 2000-09-22
US09/667,357 US6589504B1 (en) 2000-09-22 2000-09-22 Compounds and methods for diagnosing and treating amyloid-related conditions
US09667357 2000-09-22
US60234611 2000-09-22
PCT/US2001/029010 WO2002024652A1 (en) 2000-09-22 2001-09-17 Compounds and methods for diagnosing and treating amyloid-related conditions

Publications (1)

Publication Number Publication Date
AU2001289123A1 true AU2001289123A1 (en) 2002-04-02

Family

ID=22882072

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001289123A Abandoned AU2001289123A1 (en) 2000-09-22 2001-09-17 Compounds and methods for diagnosing and treating amyloid-related conditions

Country Status (6)

Country Link
US (2) US6589504B1 (en)
EP (1) EP1318982A1 (en)
AR (1) AR034153A1 (en)
AU (1) AU2001289123A1 (en)
PE (1) PE20020452A1 (en)
WO (1) WO2002024652A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7311893B2 (en) 2000-07-25 2007-12-25 Neurochem (International) Limited Amyloid targeting imaging agents and uses thereof
US20020115717A1 (en) * 2000-07-25 2002-08-22 Francine Gervais Amyloid targeting imaging agents and uses thereof
WO2002075312A1 (en) 2001-03-19 2002-09-26 Gyros Ab Characterization of reaction variables
DE10230838B4 (en) * 2002-07-04 2005-02-03 Mediquant Gmbh Diagnostic use of pharmaceutical substances
US20080063599A1 (en) * 2002-11-18 2008-03-13 Jorge Setoain Quinquer Compounds Which Can Be Used To Diagnose And Monitor Diseases Associated With The Formation Of Amyloid Protein Fibrils
PL1791904T3 (en) * 2004-09-24 2015-02-27 Univ Maryland Method of treating organophosphorous poisoning
US9132135B2 (en) * 2004-09-24 2015-09-15 University Of Maryland, Baltimore Method of treating organophosphorous poisoning
WO2006110477A2 (en) * 2005-04-07 2006-10-19 Astrum Therapeutics Pty. Ltd. Compounds to treat amyloidosis and prevent death of beta-cells in type 2 diabetes mellitus
WO2007056580A2 (en) * 2005-11-08 2007-05-18 Pharmadyn, Inc. Methods and compositions for treating diseases associated with pathogenic proteins
US7737183B2 (en) * 2006-10-17 2010-06-15 The Regents Of The University Of California β-amyloid and neurofibrillary tangle imaging agents
WO2014036528A2 (en) 2012-08-31 2014-03-06 Ixchel Pharma, Llc Agents useful for treating obesity, diabetes and related disorders
US11357770B2 (en) 2016-07-01 2022-06-14 Alterity Therapeutics Limited Method of treating immunoglobulin light chain amyloidosis
WO2023080687A1 (en) * 2021-11-03 2023-05-11 가천대학교 산학협력단 High-speed mass screening method for amyloid-beta multimer inhibitory drug and composition comprising doxorubicin or derivative thereof for inhibiting oligomerization or fibrillation of amyloid-beta

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3646019A (en) 1968-10-26 1972-02-29 Smith Kline French Lab Anticestode hydrazinoquinolines
JPS5867616A (en) 1981-10-15 1983-04-22 Tanabe Seiyaku Co Ltd Enteric microcapsule and its preparation
IT1192015B (en) 1986-06-27 1988-03-31 Tecnocar Spa FILTER FOR INTERNAL COMBUSTION ENGINE LUBRICANTS WITH RESERVE OF ADDITIVES
US5164404A (en) 1991-03-15 1992-11-17 Neurosearch A/S Hydrazone derivatives and their use
WO1994028412A1 (en) 1993-05-28 1994-12-08 The Miriam Hospital Composition and method for in vivo imaging of amyloid deposits
FR2715155B1 (en) 1994-01-19 1996-07-26 Mayoly Spindler Monoamine oxidase B inhibitors and methods of preparing them.
US6417178B1 (en) 1994-07-19 2002-07-09 University Of Pittsburgh Amyloid binding nitrogen-linked compounds for the antemortem diagnosis of alzheimer's disease, in vivo imaging and prevention of amyloid deposits
US6168776B1 (en) 1994-07-19 2001-01-02 University Of Pittsburgh Alkyl, alkenyl and alkynyl Chrysamine G derivatives for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
GB9416007D0 (en) 1994-08-08 1994-09-28 Erba Carlo Spa Anthracyclinone derivatives
EP1110945A3 (en) 1995-05-01 2003-05-07 University Of Pittsburgh Azocompounds for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
US5972956A (en) 1995-11-02 1999-10-26 Warner-Lambert Company Inhibition of amyloidosis by 9-acridinones
US5955472A (en) 1995-11-02 1999-09-21 Warner-Lambert Company Naphthylazo inhibition of amyloidosis
WO1997026919A2 (en) 1996-01-24 1997-07-31 Warner-Lambert Company Method of imaging amyloid deposits
DE69736777T2 (en) 1996-03-29 2007-08-23 Ortho-Mcneil Pharmaceutical, Inc. AMIDINOHYDRAZONE AS PROTEASE INHIBITORS
US6054114A (en) 1996-05-08 2000-04-25 Massachusetts Institute Of Technology Organometallic ligands for the localization and quantification of amyloid in vivo and in vitro
GB9613433D0 (en) 1996-06-26 1996-08-28 Pharmacia Spa Fluoro labelled anthracyclinone and anthracycline derivatives
DE19649971A1 (en) 1996-11-19 1998-05-28 Diagnostikforschung Inst Optical diagnostics for the diagnosis of neurodegenerative diseases using near-infrared radiation (NIR radiation)
WO2000010614A1 (en) 1998-08-20 2000-03-02 Regents Of The University Of California METHODS FOR LABELING β-AMYLOID PLAQUES AND NEUROFIBRILLARY TANGLES

Also Published As

Publication number Publication date
EP1318982A1 (en) 2003-06-18
US6589504B1 (en) 2003-07-08
AR034153A1 (en) 2004-02-04
PE20020452A1 (en) 2002-05-17
WO2002024652A1 (en) 2002-03-28
WO2002024652B1 (en) 2002-06-27
US20030219377A1 (en) 2003-11-27

Similar Documents

Publication Publication Date Title
AU2002224949A1 (en) Method and device for measuring levels
AU2001227966A1 (en) Methods for treating tumors
AU7883700A (en) Methods and apparatus for treating teeth
GB9808764D0 (en) Magnetic stimulators for neuro-muscular tissue
AU2001268331A1 (en) Methods for diagnosing and treating thalamocortical dysrhythmia
AU3263901A (en) Methods for treating pervasive development disorders
AU2001238369A1 (en) Method for treating thyroid disorders
HK1047432A1 (en) Hemisynthetic method and new compounds
GB9907666D0 (en) Alertness tester
AU2002215125A1 (en) Well treatment method
EP1223932A4 (en) Compounds and methods
AU2001231104A1 (en) Methods for treating diabetes
EP1146790A4 (en) Compounds and methods
AU2001284865A1 (en) Methods for diagnosing and treating dysautonomia and other dysautonomic conditions
EP1102535A4 (en) Compounds and methods
AU2001289123A1 (en) Compounds and methods for diagnosing and treating amyloid-related conditions
GB2368641B (en) Methods and compositions for assaying analytes
AU2001262978A1 (en) Method and apparatus for interference reduction
AU2001279850A1 (en) Method and arrangement for studsystem
HUP0103473A3 (en) Phosphoglycolipid and methods for its use
AU5603400A (en) Device and method for testing tissue
GB0004232D0 (en) Diagnostic method
AU2003292231A1 (en) Methods for diagnosing and treating schizophrenia
AU2001218024A1 (en) Methods for treating and preventing alopecia
GB0029270D0 (en) Diagnostic method